Home / Resource Library / Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (>75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (>75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma